Log in

Relevant bibliographies by topics / Prostate syndrome / Journal articles

To see the other types of publications on this topic, follow the link: Prostate syndrome.

Journal articles on the topic 'Prostate syndrome'

Author: Grafiati

Published: 6 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Prostate syndrome.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Yakovlev, Andrey V., Elena N. Saverskaya, and Anton V. Ershov. "Efficacy and safety of bioregulatory peptides in the treatment of prostate diseases: a review." Consilium Medicum 26, no. 7 (2024): 440–44. http://dx.doi.org/10.26442/20751753.2024.7.202801.

Full text

Abstract:

The article describes the risk factors, pathogenetic mechanisms of development of various prostate diseases and highlights the problems in their treatment. Information on regulatory peptides and their mechanism of action is presented. Clinical studies proving the high effectiveness of bioregulatory peptides in the treatment of chronic prostatitis, chronic pelvic pain syndrome and benign prostatic hyperplasia are presented. The analysis was carried out and evidence of the effectiveness of domestic drugs Prostatex and Prostateks Plus in the treatment of prostate diseases was presented.

APA, Harvard, Vancouver, ISO, and other styles

2

Di Francesco, Simona, and Raffaele Tenaglia. "Metabolic Syndrome and Aggressive Prostate Cancer at Initial Diagnosis." Hormone and Metabolic Research 49, no. 07 (2017): 507–9. http://dx.doi.org/10.1055/s-0043-109866.

Full text

Abstract:

AbstractLinks between metabolic syndrome and prostate cancer after androgen deprivation therapy are emerging. The aim of the research was to investigate the association of metabolic syndrome and aggressive prostate malignancy, at initial diagnosis, without the influence of hormonal treatment. Retrospective analysis of 133 patients with prostate tumor diagnosis between 2007 and 2009 was conducted. Patients with prostate cancer were subdivided in 2 groups according to Gleason score: Gleason score≥7 as high-grade prostate tumor (Group 1) and <7 (Group 2) as low-grade prostate tumor. Metabolic

APA, Harvard, Vancouver, ISO, and other styles

3

Hirsch, Ronald L. "Transurethral Prostate Resection Syndrome." Critical Care Medicine 19, no. 8 (1991): 1094. http://dx.doi.org/10.1097/00003246-199108000-00028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Moskaluk, Christopher A. "Vanishing Prostate Cancer Syndrome." American Journal of Surgical Pathology 29, no. 4 (2005): 561–63. http://dx.doi.org/10.1097/01.pas.0000152567.85689.43.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Abufaraj, Mohammad, Raghad Ramadan, and Amro Alkhatib. "Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review." Current Oncology 31, no. 3 (2024): 1618–32. http://dx.doi.org/10.3390/curroncol31030123.

Full text

Abstract:

Neuroendocrine prostate cancer (NEPC) is a rare subtype of prostate cancer (PCa) that usually results in poor clinical outcomes and may be accompanied by paraneoplastic syndromes (PNS). NEPC is becoming more frequent. It can initially manifest as PNS, complicating diagnosis. Therefore, we reviewed the literature on the different PNS associated with NEPC. We systematically reviewed English-language articles from January 2017 to September 2023, identifying 17 studies meeting PRISMA guidelines for NEPC and associated PNS. A total of 17 articles were included in the review. Among these, Cushing’s

APA, Harvard, Vancouver, ISO, and other styles

6

Chowdhury, Rezaul Haider, Sumon Rahman Chowdhury, Tasnuva Tanzil, and Md Minhazul Alam. "Ectopic Cushing’s Syndrome From Prostatic Adenocarcinoma: A Rare Clinical Entity." Journal of Chittagong Medical College Teachers' Association 31, no. 1 (2020): 125–29. http://dx.doi.org/10.3329/jcmcta.v31i1.66752.

Full text

Abstract:

A 61-year-old man known to have metastatic prostate adenocarcinoma was seen at Changi General Hospital, Singapore, because of severe hypokalaemia due to ACTH dependent Cushing’s syndrome. He underwent a Dotate PET CT which showed increased DOTA-NOC-avidity in the right side of the prostate gland. Subsequent immunohistochemical staining of prostate biopsy sample documented ACTH, synaptophysin and CD 56 positivity. He was suggested medical management for prostate cancer complicated by Cushing's syndrome. Unfortunately, Cushing’s syndrome was not controlled and the patient’s clinical condition pr

APA, Harvard, Vancouver, ISO, and other styles

7

В.Х., Битеев, Зубков И.В., Овсюков А.А. та ін. "Терапия препаратом «Простатекс плюс» в раннем послеоперационном периоде у больных, перенесших оперативные вмешательства на предстательной железе". International Journal of Medicine and Psychology 7, № 5 (2024): 27–33. http://dx.doi.org/10.58224/2658-3313-2024-7-5-27-33.

Full text

Abstract:

в статье представлен анализ данных по использованию препарата «Простатекс плюс» у больных перенесших трансуретральную энуклеацию гиперплазии простаты. По данным результатов проведенного исследования можно говорить об усилении восстановительных процессов у больных после оперативного вмешательства на предстательной железе в объеме трансуретральной энуклеации гиперплазии простаты с применением постоперационной терапии препарата «Простатекс плюс» в течение 20 дней, что доказывается практически полным невилированием болевого синдрома и значительным снижением дизурических явлений в раннем послеопера

APA, Harvard, Vancouver, ISO, and other styles

8

Lund Håheim, Lise. "Metabolic syndrome and prostate cancer." Expert Review of Endocrinology & Metabolism 2, no. 5 (2007): 633–40. http://dx.doi.org/10.1586/17446651.2.5.633.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Haukaas, Svein Andreas, Ole Johan Halvorsen, Svein Jacob Tjoflaat Nygaard, and Elisabeth Paus. "Cushing’s Syndrome in Prostate Cancer." Urologia Internationalis 63, no. 2 (1999): 126–29. http://dx.doi.org/10.1159/000030431.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Glendenning, J., and V. Khoo. "Sweet's syndrome in prostate cancer." Prostate Cancer and Prostatic Diseases 11, no. 4 (2008): 397–98. http://dx.doi.org/10.1038/sj.pcan.4501029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Glode, L. Michael. "Metabolic syndrome and prostate cancer." Cancer 112, no. 10 (2008): 2103–5. http://dx.doi.org/10.1002/cncr.23511.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Krupin, Valentin N., Alexey V. Krupin, Anna N. Belova, and Natalya A. Nashivochnikova. "The state of prostate hemodynamics in patients with myophascial pain syndrome." Urologicheskie vedomosti 7, no. 4 (2017): 39–43. http://dx.doi.org/10.17816/uroved7439-43.

Full text

Abstract:

The aim of this study was to evaluate the state of blood flow in prostate in 59 men with chronic pelvic pain due to myofascial syndrome in the absence of clinical manifestations of chronic prostatitis and its dynamics against the background of the treatment. The results of the study revealed a reliable relationship between the severity of blood flow disorders in the prostate and the intensity of pain symptoms caused by myofascial syndrome. It was concluded that the hemodynamic disorders of the prostate caused by myofascial syndrome are important in the possible formation of clinical symptoms o

APA, Harvard, Vancouver, ISO, and other styles

13

Bloomer, Zachary, Jennifer Teague, and Nicole Vietor. "Ectopic Cushing’s From Metastatic Prostate Cancer." Journal of the Endocrine Society 5, Supplement_1 (2021): A757. http://dx.doi.org/10.1210/jendso/bvab048.1539.

Full text

Abstract:

Abstract Objective: Ectopic ACTH production from malignancy is a rare etiology of Cushing’s syndrome. The most common tumors associated with this syndrome include small cell lung cancer, pancreatic neuroendocrine tumors, pheochromoctoma, thymic carcinoma, and bronchial carcinoma. Metastatic prostate cancer does not commonly produce ACTH. Here, we present a rare case of Cushing’s syndrome due to metastatic prostate cancer. Case Report: Patient is a 64 year old man with a 2 year history of castrate-resistant prostate cancer who was admitted for the 2nd time in 1 month for profound weakness and n

APA, Harvard, Vancouver, ISO, and other styles

14

Ramos, R., F. Lopes, T. Rodrigues, N. Rolim, I. Rodrigues, and H. Monteiro. "Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome." Case Reports in Urology 2013 (2013): 1–2. http://dx.doi.org/10.1155/2013/459618.

Full text

Abstract:

Introduction. Hemolytic uremic syndrome (HUS) is characterized by endothelial dysfunction, consumption thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. HUS generally has a dismal prognosis, except when associated with gastroenteritis caused by verotoxin-producing bacteria. Cancer associated HUS is uncommon, and there are only scarce reports on prostate cancer presenting with HUS.Case Presentation. A 72-year-old man presented to the emergency department with oliguria, hematuria, and hematemesis. Clinical evaluation revealed acute renal failure, hemolysis, normal blo

APA, Harvard, Vancouver, ISO, and other styles

15

Adlington, Daniel, Jason Moore, and Coralie Bingham. "Remission of Membranous Nephropathy after Treatment of Localised Prostate Cancer." Case Reports in Nephrology and Dialysis 9, no. 2 (2019): 79–84. http://dx.doi.org/10.1159/000500948.

Full text

Abstract:

Membranous nephropathy is a cause of the nephrotic syndrome in adults; it can be a primary or secondary process. Secondary causes include solid organ and lymphoid malignancies. Prostate cancer has been reported as the second most common causative malignancy. Remission of membranous nephropathy following treatment of metastatic prostate cancer is well established. In this case, we describe a patient with localised prostate cancer who developed severe nephrotic syndrome (urine protein creatinine ratio 1,616 mg/mmol and serum albumin 17 g/L) secondary to membranous nephropathy. The prostate cance

APA, Harvard, Vancouver, ISO, and other styles

16

Zorba, Orhan Ünal, Hakkı Uzun, Görkem Akça, and Selim Yazar. "The Effect of Different Metabolic Syndrome." American Journal of Men's Health 11, no. 1 (2016): 158–63. http://dx.doi.org/10.1177/1557988316638654.

Full text

Abstract:

Because various criteria are used to define metabolic syndrome (MetS), this study examines the most relevant definition for patients with benign prostatic enlargement (BPE). Most studies regarding the link between MetS and BPE/lower urinary tract symptoms (LUTS) have used the National Cholesterol Education Program Adult Treatment Panel III criteria for diagnosis, while a few have used criteria from the International Diabetes Federation and/or American Heart Association. Patients with LUTS due to BPE are classified as having MetS or not by the aforementioned three definitions. Prostate volume,

APA, Harvard, Vancouver, ISO, and other styles

17

Goris Gbenou, Maximilien C. "The influence of obesity in patients with prostate cancer - Review of the literature." Functional Foods in Health and Disease 3, no. 4 (2013): 80. http://dx.doi.org/10.31989/ffhd.v3i4.63.

Full text

Abstract:

Recent studies have demonstrated an association between higher body mass index and increased aggressiveness in prostate cancer. The present narrative review, based on a search of Medline® and Embase® databases from October 1982 to October 2012, explores the relationship between higher body mass index and localized prostate cancer. In particular, the current epidemiological and mechanistic evidence for interactions between obesity and prostate cancer are discussed. Obesity is associated with alterations in androgen levels, decreased sex hormone binding globulin and increased estrogen levels, in

APA, Harvard, Vancouver, ISO, and other styles

18

Wang, Xiaolong, Yiming Wang, Christian Gratzke, et al. "Ghrelin Aggravates Prostate Enlargement in Rats with Testosterone-Induced Benign Prostatic Hyperplasia, Stromal Cell Proliferation, and Smooth Muscle Contraction in Human Prostate Tissues." Oxidative Medicine and Cellular Longevity 2019 (November 22, 2019): 1–14. http://dx.doi.org/10.1155/2019/4748312.

Full text

Abstract:

Epidemiologic studies revealed a context between lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and metabolic syndrome. However, molecular mechanisms underlying this relationship are largely unknown. Prostate enlargement and increased prostate smooth muscle tone are important factors in the pathophysiology of LUTS suggestive of BPH. In the present study, we studied effects of the metabolic hormone ghrelin on prostate enlargement in rats with experimentally induced BPH, growth of cultured stromal cells from human prostate (WPMY-1), and smooth muscle contrac

APA, Harvard, Vancouver, ISO, and other styles

19

Borowski, Artur, and Lucyna Siemińska. "SEX STEROIDS AND ADIPOKINES IN MEN WITH PROSTATE CANCER AND THEIR RELATIONSHIP WITH OBESITY AND METABOLIC SYNDROME." Wiadomości Lekarskie 73, no. 1 (2020): 180–87. http://dx.doi.org/10.36740/wlek202001134.

Full text

Abstract:

Prostate cancer is the most commonly diagnosed cancer among men in the world and in Poland it is the second cause of death in men suffering from cancer. Recent evidence suggests that obesity is associated with prostate cancer. Increased BMI correlates with aggressive disease and with higher risk of recurrence and mortality in prostate cancer patients. Obesity can promote the progression of prostate cancer through endocrine disturbances, mainly in sex steroids, through chronic inflammation resulting in altered production of adipokines, peripheral insulin resistance with hyperinsulinemia and oxi

APA, Harvard, Vancouver, ISO, and other styles

20

Fleshner, Neil E., and Bimal Bhindi. "Metabolic syndrome and diabetes for the urologist." Canadian Urological Association Journal 8, no. 7-8 (2014): 159. http://dx.doi.org/10.5489/cuaj.2314.

Full text

Abstract:

Type 2 diabetes has a number of know urological consequences. Epidemiologic and clinical data suggest a link between metabolic syndrome and prostatic diseases such as benign prostatic hyperplasia (BPH) and prostate cancer. Recent studies have identified metformin as a viable treatment for patients with type 2 diabetes and prostate cancer.

APA, Harvard, Vancouver, ISO, and other styles

21

Efanova, E. V., Zh A. Startseva, S. A. Fursov, A. L. Chernyshova, and O. A. Tkachuk. "Features of Radiation Reactions in Patients with Prostate Cancer with Metabolic Syndrome on the Background of Thermoradiotherapy." MEDICAL RADIOLOGY AND RADIATION SAFETY 70, no. 4 (2025): 102–5. https://doi.org/10.33266/1024-6177-2025-70-4-102-105.

Full text

Abstract:

Background: Prostate cancer (PC) is one of the most common cancers in men. According to the statistics of the Russian Federation for 2023, prostate cancer ranks 1st among malignant neoplasms in men (19.1 %) and 3rd (8.3 %) in the structure of mortality from malignant neoplasms in the male population. One of the main methods of treating prostate cancer is remote radiation therapy, with a combination of radiotherapy and local hyperthermia, the term thermoradotherapy is used. There has been a steady increase in patients with metabolic syndrome (MS) among prostate cancer patients. Given the comple

APA, Harvard, Vancouver, ISO, and other styles

22

Raymond, Victoria M., Bhramar Mukherjee, Fei Wang, et al. "Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome." Journal of Clinical Oncology 31, no. 14 (2013): 1713–18. http://dx.doi.org/10.1200/jco.2012.44.1238.

Full text

Abstract:

Purpose Prostate cancer has been described as a component tumor of Lynch syndrome (LS), with tumors obtained from mutation carriers demonstrating the DNA mismatch repair deficiency phenotype. Previous studies quantifying prostate cancer risk in LS have provided conflicting results. Methods We examined cancer histories of probands and their first- through fourth-degree relatives for 198 independent mutation-positive LS families enrolled in two US familial cancer registries. Modified segregation analysis was used to calculate age-specific cumulative risk or penetrance estimates, with accompanyin

APA, Harvard, Vancouver, ISO, and other styles

23

Dr., Tharini S., and Mahesh Kumar Dr. "Superior orbital fissure syndrome due to Metastatic prostatic malignancy: A Case Report." International Multispeciality Journal of Health 3, no. 9 (2017): 305–8. https://doi.org/10.5281/zenodo.1188145.

Full text

Abstract:

<em> Superior orbital fissure syndrome (SOFS) is a rare disease. So when a case of this came at Aravind Eye Institute, a detailed case report was prepared to publish. A 56 years old male patient, a known case of prostatic malignancy with skeletal metastasis presented with ptosis, exotropia, diminished pupillary reflex and limitations in extraocular movements of left eye. MRI brain revealed diffuse skull base and leptomeningeal metastasis. Whole body CT scan showed metastasis in ribs, scapula and in pelvic bones. He was diagnosed to have superior orbital fissure syndrome due to metastatic

APA, Harvard, Vancouver, ISO, and other styles

24

Javed, Sidra. "Urate Nephropathy from Tumor Lysis Syndrome in an Undiagnosed Case of Prostate Cancer." Current Oncology 28, no. 1 (2021): 440–44. http://dx.doi.org/10.3390/curroncol28010046.

Full text

Abstract:

Prostate cancer can masquerade as just normocytic anemia and thrombocytopenia, thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), or tumor lysis syndrome (TLS). We are reporting an intriguing case of metastatic prostate cancer which remained undiagnosed until the patient showed signs of tumor lysis syndrome (TLS), leading to urate nephropathy requiring urgent hemodialysis. Tumor lysis syndrome is an oncological emergency but an exceedingly rare complication in non-hematological malignancies, including prostate cancer. It is challenging to recognize features of TLS in a

APA, Harvard, Vancouver, ISO, and other styles

25

Xu, Xuncan, Xinru Tang, Yingwen Du, Canbin Lin, Ming Chen, and Zhimin Zhao. "Exploring the Androgen Deficiency Syndrome After Endocrine Therapy for Prostate Cancer Based on the "Yin-Ping Yang-Mi" TheoryReview Article." Cell Conflux 1 (May 14, 2025): e154. https://doi.org/10.71321/xj2h8w39.

Full text

Abstract:

Androgen deficiency syndrome (ADS) is a subsequent condition that arises after endocrine therapy for prostate cancer. It manifests as a reduction in testosterone levels accompanied by symptoms such as soreness and weakness of low back and knees, fatigue, hot flushes, and night sweats. This syndrome represents an imbalance between the opposing and complementary forces of yin and yang within the body. Utilizing the yin-yang theory of traditional Chinese medicine, this study analyzes the dynamic interplay of yin and yang associated with androgen deficiency syndrome after endocrine therapy for pro

APA, Harvard, Vancouver, ISO, and other styles

26

Kleinová, Patrícia, Matej Vnučák, Karol Graňák, Monika Beliančinová, Tímea Blichová, and Ivana Dedinská. "Is Minimal Change Disease Associated with Prostate Cancer or Is Age Just a Number?" Reports 7, no. 3 (2024): 70. http://dx.doi.org/10.3390/reports7030070.

Full text

Abstract:

Background: Prostate cancer is the most common malignancy in men. Secondary nephrotic syndrome, a feature of paraneoplastic syndrome, occurs in 11% of cases and is mainly caused by membranous glomerulopathy. The association between minimal change disease and prostate cancer is rare. Only one cause has been described in the available literature. Case presentation: We present the case of a 77-year-old patient who was admitted to our department with stage 3 acute kidney injury and with nephrotic syndrome with anasarca (creatinine: 168 µmol/L, eGFR: 33 mL/min/1.73 m2, albumin: 18.5 g/L, total chol

APA, Harvard, Vancouver, ISO, and other styles

27

Gilling, Peter J. "The metabolic syndrome and the prostate." BJU International 121, no. 5 (2018): 675. http://dx.doi.org/10.1111/bju.14095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Hsing, Ann W., Lori C. Sakoda, and Streamson C. Chua. "Obesity, metabolic syndrome, and prostate cancer." American Journal of Clinical Nutrition 86, no. 3 (2007): 843S—857S. http://dx.doi.org/10.1093/ajcn/86.3.843s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Leone, Gianmarco, Marcello Tucci, Consuelo Buttigliero, et al. "Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer." Endocrine-Related Cancer 25, no. 1 (2018): R1—R9. http://dx.doi.org/10.1530/erc-17-0355.

Full text

Abstract:

Antiandrogen withdrawal syndrome is an unpredictable event diagnosed in patients with hormone-sensitive prostate cancer treated with combined androgen blockade therapy. It is defined by prostate-specific antigen value reduction, occasionally associated with a radiological response, that occurs 4–6 weeks after first-generation antiandrogen therapy discontinuation. New-generation hormonal therapies, such as enzalutamide and abiraterone acetate, improved the overall survival in patients with metastatic castration-resistant prostate cancer, and recent trials have also shown the efficacy of abirate

APA, Harvard, Vancouver, ISO, and other styles

30

Post, Jennifer M., Jennifer L. Beebe-Dimmer, Hal Morgenstern, et al. "The Metabolic Syndrome and Biochemical Recurrence following Radical Prostatectomy." Prostate Cancer 2011 (2011): 1–6. http://dx.doi.org/10.1155/2011/245642.

Full text

Abstract:

Metabolic syndrome refers to a set of conditions that increases the risk of cardiovascular disease and has been associated with an increased risk of prostate cancer, particularly among African American men. This study aimed to estimate the association of metabolic syndrome with biochemical recurrence (BCR) in a racially diverse population. Among 383 radical prostatectomy patients, 67 patients had documented biochemical recurrence. Hypertension was significantly, positively associated with the rate of BCR (hazard ratio (HR) = 2.1; 95% CI = 1.1, 3.8). There were distinct racial differences in th

APA, Harvard, Vancouver, ISO, and other styles

31

Wu, Shuiqing, Haiqing He, Yinhuai Wang, Ran Xu, Bin Zhu, and Xiaokun Zhao. "Association between benign prostate hyperplasia and metabolic syndrome in men under 60 years old: a meta-analysis." Journal of International Medical Research 47, no. 11 (2019): 5389–99. http://dx.doi.org/10.1177/0300060519876823.

Full text

Abstract:

Objective To assess the potential relationship between benign prostate hyperplasia (BPH) and metabolic syndrome in men under 60 years old. Methods We searched the Medline, Embase, and Web of Science databases for studies of patients with metabolic syndrome and BPH using the key words ‘metabolic syndrome’, ‘benign prostatic hyperplasia’, and ‘BPH’. The odds ratios (ORs) and 95% confidence intervals (95%CIs) were extracted from the included studies and the role of metabolic syndrome in BPH and its characteristics (International Prostate Symptom Score (IPSS), total prostate volume (TPV), postvoid

APA, Harvard, Vancouver, ISO, and other styles

32

Aboyan, I. A., S. V. Grachev, S. M. Pakus, and K. I. Badyan. "Efficiacy of Prostatex Plus in the prevention of prostate biopsy complications." Urology Herald 12, no. 6 (2025): 5–17. https://doi.org/10.21886/2308-6424-2024-12-6-5-17.

Full text

Abstract:

Introduction. The most frequent complications after fine-needle biopsy of the prostate gland are infections and inflammations, which can occur in up to 17 % of cases. Currently, there is no standardised protocol for preventing infectious complications, including the choice of medication, duration, and timing of administration. Objective. To evaluate the effectiveness of Prostatex Plus in combination therapy after prostate biopsy compared with the generally accepted approach to patient management. Materials and methods. A prospective study involved 62 men undergoing examination and treatment at

APA, Harvard, Vancouver, ISO, and other styles

33

Kruglov, V. A., F. R. Asfandiyarov, S. N. Vybornov, and K. S. Seyidov. "Treatment of patients with chronic pelvic pain syndrome: result of single-center follow up study." Herald Urology 6, no. 4 (2019): 27–35. http://dx.doi.org/10.21886/2308-6424-2018-6-4-27-35.

Full text

Abstract:

Introduction. Chronic pelvic pain syndrome is an urgent and widely discussed problem in the medical community. Despite the efforts made by a wide range of specialists, there is currently no universally accepted universal approach to the diagnosis and treatment of this condition. The article provides a description and results of applying its own approach to the management of patients with chronic pelvic pain syndrome.Purpose of research. The aim of the work was to improve the practical results of treatment of patients suffering from chronic pelvic pain syndrome.Materials and methods. The result

APA, Harvard, Vancouver, ISO, and other styles

34

İsayev, Nurlan, Levent Yücel, Hatice Seçil Akyıldız, Hazan Başak, Süha Beton, and Cem Meço. "Prostate Cancer Metastasis Causing Occipital Condyle Syndrome: A Rare Clinical Entity." International Journal of Medical Science and Clinical Invention 8, no. 03 (2021): 5272–74. http://dx.doi.org/10.18535/ijmsci/v8i03.03.

Full text

Abstract:

Introduction: Prostate cancer metastasis to clivus and occipital condyle are extremely rare and only a few cases are published. We present a case with metastasis of prostate cancer to skull base causing occipital condyle syndrome (OCS). Case Presentation: A-56-year-old man was referred to our clinic with complaints of dysphagia for two months and headache on his right occipital region for five months. There was deviation of the tongue to the right side in his physical examination. He was performed surgery for prostate adenocarcinoma for 2 years ago. Magnetic resonance imaging and compute

APA, Harvard, Vancouver, ISO, and other styles

35

Balestrieri, Antonio, Elena Magnani, and Fiorella Nuzzo. "Unusual Cushing’s Syndrome and Hypercalcitoninaemia due to a Small Cell Prostate Carcinoma." Case Reports in Endocrinology 2016 (2016): 1–5. http://dx.doi.org/10.1155/2016/6308058.

Full text

Abstract:

A 75-year-old man was hospitalized because of severe hypokalaemia due to ACTH dependent Cushing’s syndrome. Total body computed tomography (TBCT) and 68 Gallium DOTATATE PET/CT localized a voluminous prostate tumour. A subsequent transurethral prostate biopsy documented a small cell carcinoma positive for ACTH and calcitonin and negative for prostatic specific antigen (PSA) at immunocytochemical study; serum prostatic specific antigen (PSA) was normal. Despite medical treatments, Cushing’s syndrome was not controlled and the patient’s clinical condition progressively worsened. Surgical resecti

APA, Harvard, Vancouver, ISO, and other styles

36

Zhou, Ya-nan, Jin-qi Song, Gang-liang Tu, Hui Xu, and Meng Ding. "The recent advances in Vascular endothelial growth factor and metabolic syndrome in prostate cancer." Nepalese Journal of Cancer 5, no. 1 (2021): 13–18. http://dx.doi.org/10.3126/njc.v5i1.41318.

Full text

Abstract:

Prostate cancer is one of the most common male malignant tumors in Western countries. In the United States, there are about 170,000 new cases of prostate cancer in 2019, ranking second only to lung cancer.1, 2 In recent years, the incidence of prostate cancer in China is gradually increasing occupying the third place among male urogenital malignancies. The metastasis of prostate cancer mainly depends on blood vessels and lymphatic vessels, and the late discovery and poor prognosis of patients are the main reasons for the high fatality rate.2 Relevant epidemiological studies on immigration have

APA, Harvard, Vancouver, ISO, and other styles

37

Layman, Awo Akosua K., Shivam Joshi, and Sanjeev Shah. "Metastatic prostate cancer presenting as tumour-induced osteomalacia." BMJ Case Reports 12, no. 7 (2019): e229434. http://dx.doi.org/10.1136/bcr-2019-229434.

Full text

Abstract:

Tumour-induced osteomalacia (TIO), or oncogenic osteomalacia, is a paraneoplastic syndrome marked by hypophosphataemia, renal phosphate wasting, bone pain, weakness, and fractures. The syndrome has been reported with both benign and malignant tumours including parotid gland basal cell tumours, thyroid carcinomas, colon adenocarcinomas, and prostate cancer. Often, the syndrome is marked by an insidious course during which patients present with generalised bony pain and weakness, which do not resolve until the underlying tumour is identified and treated. We present a case of a patient with Parki

APA, Harvard, Vancouver, ISO, and other styles

38

Lim, Ee Jean, Mengyue Su, B. M. Saiduzzaman, et al. "Oligometastatic Prostate Cancer—The Middle Child Syndrome." Journal of Clinical Medicine 12, no. 23 (2023): 7198. http://dx.doi.org/10.3390/jcm12237198.

Full text

Abstract:

Oligometastatic prostate cancer is an evolving clinical entity as more data from novel imaging tools such as PSMA PET/CT emerges. Recognition of this disease entity allows for unique interventions which differ from conventional treatment of metastatic prostate cancers such as the initiation of chemotherapy. With metastasis-directed therapy (MDT), there is potential for early eradication of limited disease metastases and a delay in systemic treatment with its associated treatment-related toxicities. This review explores the current evidence and outcomes of different metastasis-directed therapie

APA, Harvard, Vancouver, ISO, and other styles

39

Haraldsdottir, Sigurdis, Heather Hampel, Lai Wei, et al. "Prostate cancer incidence in males with Lynch syndrome." Journal of Clinical Oncology 31, no. 4_suppl (2013): 366. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.366.

Full text

Abstract:

366 Background: Lynch syndrome (LS) is caused by germline mutations in DNA mismatch repair (MMR) genes and increases the risk of colon and several other cancers. Prostate cancer is not currently considered part of the LS-tumor spectrum. The objective of this retrospective study was to assess whether the incidence of prostate cancer is increased above that of the general population in MMR mutation carriers. Methods: Patients who were identified as MMR mutation carriers and included in previous LS studies or evaluated at the genetics clinic at The Ohio State University were contacted and their c

APA, Harvard, Vancouver, ISO, and other styles

40

Ravindranathan, Deepak, Emilie Elise Hitron, Greta Anne Russler, Yue Xue, and Mehmet Asim Bilen. "Metastatic Prostate Cancer Manifesting as Cholestatic Jaundice: A Case Report and Review of the Literature." Case Reports in Oncological Medicine 2018 (2018): 1–4. http://dx.doi.org/10.1155/2018/1809432.

Full text

Abstract:

A paraneoplastic syndrome can often present as the first manifestation of an underlying malignancy. We report a patient who presented with cholestatic jaundice as a paraneoplastic syndrome from his newly diagnosed metastatic prostate cancer. He received initial treatment with androgen deprivation therapy followed by six cycles of docetaxel resulting in resolution of his cholestatic process, normalization of liver enzyme levels, and excellent biochemical and radiographic response. To the best of our knowledge, this is the first reported case of metastatic prostate cancer with cholestatic jaundi

APA, Harvard, Vancouver, ISO, and other styles

41

Romašovs, Andris, Aldis Puķītis, Viktorija Mokricka, and Elina Frolova. "Stauffer’s Syndrome in Patient with Metastatic Prostate Cancer." Case Reports in Urology 2019 (April 22, 2019): 1–3. http://dx.doi.org/10.1155/2019/9745301.

Full text

Abstract:

Cholestasis is a symptom that can be present in many conditions, such as bile duct obstruction by malignant mases, obstruction by gallstone, acute and chronic viral hepatitis, and autoimmune disorders, such as primary biliary and sclerosing cholangitis. Stauffer syndrome is a rare type of paraneoplastic syndrome that presents as cholestasis with absence of underlying disease. Classically Stauffer syndrome has been described in renal cell cancer patients. In literature cholestasis as manifestation of paraneoplastic syndrome has also been described in patients with prostate adenocarcinoma and pa

APA, Harvard, Vancouver, ISO, and other styles

42

Panwar, Vikrant, B. L. Pandey, U. S. Dwivedi, and Alok Singh. "Comparative clinical profile of patients of Benign Prostatic Hyperplasia (BPH) with and without Metabolic Syndrome: a prospective observational study." International Journal of Basic & Clinical Pharmacology 6, no. 10 (2017): 2452. http://dx.doi.org/10.18203/2319-2003.ijbcp20174375.

Full text

Abstract:

Background: Benign Prostatic Hyperplasia (BPH) is one of common disorder in men of old age group. The pathogenesis of BPH is multi-factorial and still not been fully elucidated. There are numerous reports which suggest possible link between several metabolic alterations known as Metabolic Syndrome. In the present study, the aim was to establish relation between Benign Prostatic Hyperplasia and Metabolic Syndrome and to find out effects of therapeutic intervention of Metabolic Syndrome on prostatic parameters.Methods: 93 patients of Benign Prostatic Hyperplasia enrolled who met qualifying crite

APA, Harvard, Vancouver, ISO, and other styles

43

Venkateswaran, Aparajit Ram, Safa F. Elzein, Emilio D. Sulpizio, Bernard Chang, and Michael P. Kosty. "Case Report: A rare presentation of prostate cancer with peritoneal carcinomatosis and malignant ascites complicated by tumor lysis syndrome." F1000Research 11 (August 18, 2022): 957. http://dx.doi.org/10.12688/f1000research.121639.1.

Full text

Abstract:

Background: Only 32 cases of prostate cancer with peritoneal carcinomatosis and ascites have currently been reported in the literature. We present the first reported case of prostate cancer with peritoneal carcinomatosis and malignant ascites whose treatment was complicated by tumor lysis syndrome along with a literature review evaluating similar cases. Case: We present a rare case of a 78-year-old retired Caucasian male with recurrent metastatic prostate cancer and malignant ascites. He had previously received definitive radiotherapy for localized prostate cancer but presented with bilateral

APA, Harvard, Vancouver, ISO, and other styles

44

Valentini, A. L., P. Ferrara, C. Manzoni, A. P. Mancini, S. Pulitanò, and L. Bonomo. "The Absence of the Verumontanum at Voiding Cystourethrography as a Sign of Prostate Maldevelopment." Advances in Urology 2011 (2011): 1–3. http://dx.doi.org/10.1155/2011/982709.

Full text

Abstract:

Prostate maldevelopment in prune-belly syndrome has only been described at necropsy. No reports are available in the “in vivo” studies. The absence of the verumontanum at voiding cystourethrography correlates with verumontanum and prostate hypoplasia. This radiographic sign can represent the earliest finding in prostate maldevelopment and might contribute to the “in vivo” assessment of the disease, especially in doubtful cases.

APA, Harvard, Vancouver, ISO, and other styles

45

Choi, W. S., C. J. Lee, S. B. Ha, et al. "860 Influence of metabolic syndrome on prostate volume and prostate specific antigen." European Urology Supplements 12, no. 1 (2013): e860. http://dx.doi.org/10.1016/s1569-9056(13)61339-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Duygulu, Gokhan, Zahide Yılmaz, Şehnaz Kılıç, and Rabia Terzi. "Tapia's syndrome secondary to metastatic prostate cancer." Neurology India 63, no. 5 (2015): 782. http://dx.doi.org/10.4103/0028-3886.166531.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Santana, Iúri Amorim de, Gustavo Souza Moura, Nivaldo Farias Vieira, and Rosana Cipolotti. "Metabolic syndrome in patients with prostate cancer." Sao Paulo Medical Journal 126, no. 5 (2008): 274–78. http://dx.doi.org/10.1590/s1516-31802008000500006.

Full text

Abstract:

CONTEXT AND OBJECTIVE: Prostate cancer (PCa) is the second most common cancer among men in Brazil. Recently, several studies have hypothesized a relationship between PCa and metabolic syndrome (MS). The aim here was to identify an association between MS and PCa. DESIGN AND SETTING: Cross-sectional study, Fundação de Beneficência Hospital de Cirurgia (FBHC) and Universidade Federal de Sergipe. METHODS: Laboratory and anthropometric parameters were compared between PCa patients (n = 16) and controls (n = 16). RESULTS: The PCa patients showed significantly greater frequency of MS than did the con

APA, Harvard, Vancouver, ISO, and other styles

48

SINGER, MERVYN, MANESH PATEL, ANDREW R. WEBB, and CATHERINE BULLEN. "Management of the transurethral prostate resection syndrome." Critical Care Medicine 18, no. 12 (1990): 1479. http://dx.doi.org/10.1097/00003246-199012000-00031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Baloh, R. W., S. E. DeRossett, T. F. Cloughesy, et al. "Novel brainstern syndrome associated with prostate carcinoma." Neurology 43, no. 12 (1993): 2591. http://dx.doi.org/10.1212/wnl.43.12.2591.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Fjellestad-Paulsen, Anne, Per-Anders Abrahamsson, Anders Bjartell, et al. "Carcinoma of the prostate with Cushing's syndrome." Acta Endocrinologica 119, no. 4 (1988): 506–16. http://dx.doi.org/10.1530/acta.0.1190506.

Full text

Abstract:

Abstract. A case is described of a patient with a smallcell prostatic carcinoma containing immunoreactive CRH, in conjunction with ACTH-dependent Cushing's syndrome. The serum concentrations of CRH, ACTH, β-endorphin and calcitonin were all found to be above normal. Post-mortem examination revealed a prostatic tumour with multiple metastases, and a diffuse hyperplasia of pituitary corticotropic cells and adrenal cortical cells. In sections of the primary prostatic tumour, immunoreactive cells were demonstrable with antisera raised against human CRH, TSH, calcitonin and somatostatin, but not wi

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!